Enamine and TBD Biodiscovery Collaborate to Provide GMP-Based Services
Enamine Ltd., a chemical research organization and producer of novel building blocks and screening libraries, and TBD Biodiscovery, a premium GMP manufacturer of fine chemicals including chemical active pharmaceutical ingredients (APIs), today announced they have entered into a collaboration agreement. The partnership aims to manage the transition of chemical synthesis of novel intermediates from laboratory to bulk scale under GMP standards utilizing Enamine’s know-how and process development expertise. This will help researchers meet the manufacturing feasibility criteria required for drug candidate selection, providing a rapid and cost effective scaled supply of new compounds.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180619005582/en/
Enamine’s catalogue of building blocks is the largest in the world and has been widely used by pharmaceutical companies for more than 15 years to develop lead compounds and drug candidates. With syntheses of these compounds first realized by Enamine, the company holds specialist knowledge that can be critical to successful scale-up. In the announced collaboration Enamine will optimize synthesis processes while TBD Biodiscovery will use the developed protocols to manufacture requested products to GMP standard.
Dr. Vladimir Ivanov, Chief of Sales and Marketing at Enamine, commented: “We recognize that the building blocks we synthesize are being incorporated into the development of new drugs. We are confident that by working in partnership with TBD Biodiscovery with their extensive experience in providing synthesis services under GMP, we can further extend the support we provide and help streamline the manufacturing process.”
Dr. Andrus Tasa, Chairman of the Management Board of TBD Biodiscovery, adds: “I have been very impressed by the creativity of Enamine’s chemists in designing new chemical synthesis. We are happy to have Enamine’s support in optimizing the chemical processes used by us for GMP manufacture.”
About Enamine Ltd. www.enamine.net
Established in Kyiv, Ukraine in 1991, Enamine is a chemical company producing building blocks and screening libraries of world reputation. The major asset of the company is the world's largest collection of building blocks: 150,000 in stock with 2,000 additions synthesized each month. These research functionalized compounds provide a significant competitive advantage to the company in supplying custom compound libraries particularly in the frame of medicinal chemistry collaborations or compound collection enhancement programs. Custom synthesis and kilogram scale up based both on fee-for-service and FTE models represent another area of business activities provided by Enamine, which are growing significantly in recent years.
About TBD Biodiscovery www.biodiscovery.eu
TBD Biodiscovery is a private company providing contract manufacturing and R&D services for biotech and pharma industry. The company has European GMP certification and offers top quality in the production of chemical APIs (both commercial and clinical batches), pre-formulations for clinical studies and excipients – everything in compliance with the strictest GMP guidelines. Since the beginning in 2006, TBD Biodiscovery is renowned for its strong experience in synthesis route design/scouting, complex multistep synthesis and upscale process development.
TBD Biodiscovery is based in Tartu, Estonia and operates worldwide; its clients’ portfolio includes customers from EU, Switzerland, US, Israel, Russia and South Korea.
Michael Bossert, +38 044 537 32 18
Head of Strategic Alliances
Dr. Olga Tšubrik, +372 747 25 01
Head of Business Development
Sarah Jeffery, +44 7771 730919
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Hilton Launches New Brand, Signia Hilton, Delivering Sophisticated Travel While Reimagining Meetings and Events22.2.2019 17:00:00 | Pressemelding
Hilton (NYSE: HLT) today announced the launch of Signia Hilton, its dynamic, new meetings-and-events-focused brand. The portfolio of hotels is setting out to transform the industry for meeting professionals and sophisticated business travelers by infusing state-of-the-art technology and design into every aspect of the guest experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005071/en/ The brand further reinforces Hilton’s commitment to innovation that meets the evolving needs of today’s travelers and will bring premium experiences to top urban and resort destinations around the world. “In our 100th year of hospitality, we are more focused than ever on providing exceptional experiences to all of our guests – and that includes evolving those experiences to meet their changing needs,” said Christopher J. Nassetta, president and CEO, Hilton. “We are proud to launch Signia Hilton, which exemplifies our innovative sp
Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans22.2.2019 16:30:00 | Pressemelding
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System. The Axonics r-SNM System is the only implantable SNM system that has received full-body MRI conditional labeling for sale in Europe1. Raymond W. Cohen, Chief Executive Officer of Axonics, said, “Without this labeling, any patient requiring an MRI scan on any body part below the head must have their neurostimulator surgically explanted prior to the MRI scan, resulting in an additional surgery for the patient and additional costs to patients and the healthcare system. This authorization of full-body MRI scans in Europe is another important milestone for Axonics, differentiating our te
Fantastec Joins Forces with Arsenal FC Launching Official Blockchain Collectibles App22.2.2019 14:30:00 | Pressemelding
Fantastec announced today its first football licensing agreement with Premier League club Arsenal FC for a new blockchain authenticated collectibles app called Fantastec SWAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005277/en/ Arsenal players appear on Fantastec SWAP in official licensing deal (Graphic: Business Wire) London-based Fantastec is a leading sports fan technology innovator, and its blockchain based ‘SWAP’ app will have broad appeal to global sports fans, gamers and sports card collectors alike. Fantastec SWAP unlocks unique and authentic club content through the app, like player autographs and exclusive footage. With its innovative blockchain technology, fans around the world can now discover, collect and swap officially licensed club collectibles with other fans with complete trust. “Fantastec SWAP is a game-changer for international football fans as well the sports collectibles industry,” commented
Volkswagen Protects Virtual Key Sharing App with Trustonic Application Protection22.2.2019 13:42:00 | Pressemelding
Volkswagen is working with mobile cyber security leader Trustonic to enable customers to use smartphones to access their vehicles, and to securely share their digital car keys to grant access to others via a smartphone app. Volkswagen is using the Trustonic Application Protection (TAP) platform to secure the mobile app and ensure that sensitive information and key transfer requests are securely displayed to, and approved by, a real authenticated user on a trusted device and not by hackers or malware simulating a user or device. “The smartphone is becoming the vehicle key of the future and our We Connect service is the interface for this today in the new Volkswagen Passat,” comments Alf Pollex, Head of Infotainment and Connected Car at Volkswagen AG. “The user installs the We Connect app on their smartphone which is then authorized via the infotainment system with a Transaction Number. The Mobile Key will be compatible with Android-based Samsung devices. No mobile network connection is
Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer22.2.2019 13:30:00 | Pressemelding
Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/ Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of
Lenovo Data Center Group Delivers Broad Edge Computing Portfolio, Expands Investments in IoT22.2.2019 13:13:00 | Pressemelding
Next week at MWC Barcelona, Lenovo Data Center Group (DCG) will showcase continued investments in its solutions supporting IoT and edge computing as part of its IoT growth plan over the next few years. Building on the momentum of its fifth consecutive quarter of profit growth, Lenovo DCG is building a portfolio that takes infrastructure to where the data is, whether that be in the traditional data center, in the cloud or increasingly, at the edge. Today, around 10 percent of enterprise-generated data is created and processed outside a traditional centralized data center or cloud. By 2022, Gartner predicts this figure will reach 75 percent. This migration is driving increased concerns around data privacy, security and regulations coupled with challenges of latency, bandwidth and downtime. Lenovo is addressing these challenges by creating a broad portfolio of edge computing offerings that address the different ways that customers want to deploy edge computing solutions for IoT use cases.